Sunday, October 4, 2026

USD/EUR Bearish By 1% In The Last 21 Sessions

USD/EUR Bearish By 1% In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 1.73% for the last 21 sessions. At 19:05 EST on Sunday, 30 April, USD/EUR (USDEUR) is $0.91.

USD/EUR's yearly highs and lows, it's 0.71% up from its 52-week low and 13.394% down from its 52-week high.

News about

  • Usd/jpy price analysis: trades nearby six-week highs, above 136.20s. According to FXStreet on Saturday, 29 April, "The first resistance would be the March 10 high at 136.99, which, once cleared, the USD/JPY will continue towards the March 9 high at 137.35. ", "A breach of the latter, the USD/JPY could dip toward April 19 daily high, turned support at 135.13, ahead of challenging the 135.00 figure."
  • Usd/jpy price analysis: rally inspired by continuation of boj’s ultra-dovish policy approaches 135.00. According to FXStreet on Friday, 28 April, "The USD/JPY pair has scaled quickly to near the crucial resistance of 135.00 after the Bank of Japan (BoJ) announced a continuation of ultra-loose monetary policy and stability in Japanese Government Bonds' (JGBs) yields band to maintain an expansionary policy stance. ", "On a four-hour scale, USD/JPY is near the edge of the horizontal resistance of the Ascending Triangle chart pattern plotted from March 15 high at 135.12. "
  • Usd/jpy jumps 100 pips to mid-134.00s on boj status quo, governor ueda eyed. According to FXStreet on Friday, 28 April, "However, challenges to sentiment emanating from the First Republic Bank (FRB), US debt ceiling expiration woes and hawkish Fed bets led by recently upbeat US inflation signals seem to prod the USD/JPY pair buyers.", "However, the BoJ also said that they will take additional easing steps without hesitation as needed while striving for market stability, which in turn propels the USD/JPY prices of late."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com